Our diverse pipeline includes innovative therapeutics and biobetters.
We focus on three key therapeutic areas: orphans, cancers and immune disorders.

HyTropin (long-acting hGH, GX-H9)

Indication	Research	Pre-Clinical	Clinical Phase			Site
			I	II	III
Adult Growth Hormone Deficiency						EU/KR
Pediatric Growth Hormone Deficiency

HyPoietin (long-acting EPO, GX-E2)

Indication	Research	Pre-Clinical	Clinical Phase			Site
			I	II	III
CKD-induced Anemia						KR

HyGrastim (long-acting G-CSF, GX-G3)

Indication	Research	Pre-Clinical	Clinical Phase			Site
			I	II	III
Neutropenia						EU

HyGlutide (long-acting GLP-1, GX-G6)

Indication	Research	Pre-Clinical	Clinical Phase			Site
			I	II	III
Type 2 Diabetes						EU

Papitrol-188 (HPV DNA Vaccine)

Indication	Regimen	Research	Pre-Clinical	Clinical Phase			Site
				I	II	III
Pre-Cervical Cancer (HSIL)	Mono						EU
Cervical Cancer	Pembrolizumab Combo						KR

Multi-Target Antibody Drug Candidates

Areas	Indication	Research	Pre-Clinical	Clinical Phase			Site
				I	II	III
Multi-Specific (Bi-, Tri-)	Cancer						KR

HyLeukin (IL-7-hyFc)

Areas	Indication	Regimen	Research	Pre-Clinical	Clinical Phase			Site
					I	II	III
Immuno-Oncology	Solid Tumor	Mono						KR
	Glioblastoma	Mono						KR
	Triple Negative Breast Cancer	Pembrolizumab combo						KR

HyLeukin (IL-7-hyFc), Co-developing with NIT

Areas	Indication	Regimen	Research	Pre-Clinical	Clinical Phase			Site
					I	II	III
Immuno-Oncology	Glioblastoma	Mono						US
		Chemo combo						US
	Skin Cancer (Melanoma, etc.)	Atezolizumab combo						US